NCT06528912

Standard Follow-up Program (SFP) for Neuro-oncology Cancer Patients Treated With Radiotherapy

Recruiting now Last updated 29 July 2024

What this trial tests

trial testing Radiotherapy in Neurological Cancer in 10,000 participants. Currently enrolling.

Timeline

1 December 2017

Primary endpoint
1 January 2040

1 January 2040

Quick facts

Lead sponsor	University Medical Center Groningen
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	10,000
Start date	1 December 2017
Primary completion	1 January 2040
Estimated completion	1 January 2040
Sites	1 location across Netherlands

Drugs / interventions tested

• Radiotherapy — full drug profile →

Conditions studied

• Neurological Cancer — all drugs for Neurological Cancer →

Sponsor

University Medical Center Groningen

Who can join

18 and older, any sex, with Neurological Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Treatment associated CNS toxicity
  Time frame: Before start of radiation therapy, at 2,5 years; 5 years 7,5 years, 10 years and 12,5 years after completion of radiation therapy.
  Treatment associated CNS Toxicity
• Radionecrosis
  Time frame: Before start of radiation therapy, at 2,5 years; 5 years 7,5 years, 10 years and 12,5 years after completion of radiation therapy.
  Treatment associated radionecrosos measured with CTCAE

Sponsor's own description

Standardised evaluation of baseline data regarding tumor-, patient- and treatment-characteristics as well as follow-up data regarding tumor- and clinical-outcome of neuro-oncology patients treated with radical/curative radiotherapy.

Motive:

Currently there is limited data on dose-effect relationships of tissues and structures in and around the brain. This lack of knowledge hampers patient selection for proton therapy, technique innovations, and accurate prediction of treatment outcome.

Goal:

To evaluate the selection for radiation treatment, obtain more knowledge on dose-effect relationships and enable insight in necessary treatment technique innovations that would improve treatment outcome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.